Hospital pharmacies face a stiff challenge as the fallout over the recent meningitis outbreak caused by tainted compounding continues: As scores of other vendors shut their doors because they failed FDA inspections, how does a hospital ensure the adequate flow of crucial admixtures?
One solution is to bring more of the sterile compounding workload back into the hospital. But this strategy has its own risks and challenges, including ensuring United States Pharmacopeia (USP) <Chapter 797> compliance, adjusting staffing and workflow, and building expensive new clean rooms and buying other high-ticket equipment and technologies. Another roadblock: steering clear of the regulatory minefield surrounding beyond-use dating (BUD).
continue reading here